Immupharma Share Discussion Threads

[lord loads of lolly] 30/8/2022 10:32

Funny how the goals posts keep shifting. Last week, everyone said today was D-day. Now it's today/tomorrow/end of the month. So which is it? According to Tim McDim, "The agreed date from the FDA for providing its written responses is 29 August 2022". In which case, why no RNS this morning? For a decision as important as this, I don't think bank holidays/time differences can be blamed for any delay. In which case, presumably the FDA has failed to meet its own deadline?

[eva_1989] 30/8/2022 10:28

make or break today/tomorrow for LTH.

Hoping for approval and hopefully IMM jumped 200/300%

[lord loads of lolly] 30/8/2022 10:23

Meanwhile, investors are getting twitchy. When I first checked 15 minutes ago, the bid was 6.489p. Currently (10.22am) it's 6.24p.

[lord loads of lolly] 30/8/2022 10:21

All depends on when the FDA released/releases the info. If yesterday (as everyone on here was saying last week), it would have been announced this morning. So presumably there's a delay from the FDA.

[1bond] 30/8/2022 10:11

I agree, but the company and its adviser have to digest all the information, which could be complex and it would be niave to think it could be announced at 7am. I'm sure we will here soon.

[lord loads of lolly] 30/8/2022 10:02

1bond - legally, market sensitive information has to be released immediately. No company has the luxury of "a day or so to digest". So either the FDA hasn't decided yet or they haven't released their decision.

[1bond] 30/8/2022 09:04

I didn't expect news this morning. It will take a day or so to digest the FDA letter I suspect.

[halfbutt] 30/8/2022 08:33

No news... surly not another disaster.... I've had this since 2008...and it never fails to surprise how much bad news can come out of a company..... is it going to be the same again ... no news is definitely not good news ?

[neo26] 26/8/2022 16:52

Are you lambo from lse

[nobbygnome] 26/8/2022 10:42

Keep the ramping going boys!

[daniel81] 26/8/2022 10:42

If we get fda approval your never see single digits again imo.

[neo26] 26/8/2022 09:33

This will be un double figures next week when fda allow phase 3.

[colsmith] 26/8/2022 08:33

The FDA said:

"The London-listed biopharmaceutical company said that the statement of purpose, objectives and proposed agenda of the meeting have already been agreed on, as has the option to provide written responses, rather than face-to-face meetings. The FDA has agreed to provide a written response by Aug. 29."

I guess if the 29th is missed IMM should issue some sort of statement, such as FDA working from home or so many COVID drugs being submitted to them they haven't had time? Still giving emergency approval for those I see.

[mudbath] 25/8/2022 13:49

Whatever lies ahead for Lupuzor; IMM remains a most remunerative share to trade.
I have just bought 89k @ 5.794p and surely there is a 25% profit awaiting.

[neo26] 25/8/2022 11:53

This was only found out after the trial, the smoking gun, patients with biomarkers benefit with drug and those without biomarkers dont..Of course u know this, right...

[neo26] 25/8/2022 11:16

NoddyThe patients were not chosen on the assumption of havin biomarkers.On third of the usa patients had biomarkers hence why the other two thirds in usa didnt benefit from drug.This new trial all patients will have biomarkers in this international phase.

[nobbygnome] 25/8/2022 10:46

You can’t say the drug ‘worked’ on the subset with anti DNA antibodies! The study was not powered to show that endpoint so we it could well be a statistical anomaly. And as benanddaddy said it apparently didn’t work on the US patients with that bio marker which shows the vagaries of stats on small numbers

[neo26] 25/8/2022 10:42

1 trading day left, fda approval on bank holiday.Tuesday gonna be fun..

[neo26] 25/8/2022 10:29

Avion are experienced, they have had 3 drugs approved by fda.The drug will be targeted on those with biomarkers, 60% of lupus patients have these biomarkers.

[bendaddy] 25/8/2022 08:12

The drug didn’t work on the anti-dsDNA US cohort and that has never been explained. And Avion are not a big pharma with experienced scientists. Have you read their website? They are a licensing, sales and marketing operation in different therapeutic areas.

[neo26] 24/8/2022 23:00

The drug works on those patients with biomarkers, avion will hav qualified scientist who will have gone over the data, they investing 25m to get it fda approved..

[nobbygnome] 24/8/2022 20:42

But the drug won’t work IMHO so they will never receive any royalty payments…..

[neo26] 24/8/2022 20:01

NoddyCurrent mkt cap is 20m, avion investing 25m to get drug through phase 3 and also into commercial production.Dont forget for usa imm have 17% royalty per annum and they have full rights for the rest of the world.I think next week will be interesting if phase 3 comes we go higher..

[nobbygnome] 24/8/2022 11:51

Fanciful figures neo. There is no way the market cap will be 150-200 million during phase III due to the past history of the drug. Around £50 million is possible however IMHO